PARP

Xi'an Xiong1, Li Cai1,2, Zhen Yang3

  • 1The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China.

Frontiers in oncology
|June 19, 2025
PubMed
概括

总胆汁酸和CA-199是接受PARPi治疗的卵巢癌患者的关键预后因素. 识别这些因素可以改善卵巢癌的治疗反应和生存预测.